Intravitreal bevacizumab for treatment of central serous chorioretinopathy

Intravitreal bevacizumab in central serous chorioretinopathy.

OBJECTIVE To evaluate the effect of intravitreal bevacizumab injection in patients with central serous chorioretinopathy (CSCR). STUDY DESIGN Quasi-experimental study. PLACE AND DURATION OF STUDY Layton Rehmatullah Benevolent Trust Eye and Cancer Hospital, Lahore, from July 2010 to April 2011. METHODOLOGY There were 43 eyes of 32 adult patients with CSCR. Patients with choroidal neovascul...

Intravitreal Avastin in the Treatment of Central Serous Chorioretinopathy

Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy

In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before...

Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for central serous chorioretinopathy.

Purpose: To evaluate subfoveal choroidal thickness (SFCT) changes after intravitreal bevacizumab (IVB) therapy for central serous chorioretinopathy (CSC) using enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT). Methods: In this retrospective study, we assessed the medical records of patients with CSC who received IVB (IVB group) or who were observed without interve...

Hemorrhagic Macular Infarction after Intravitreal Bevacizumab for Chronic Multifocal Central Serous Chorioretinopathy

We hereby report a case of hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal central serous chorioretinopathy (CSC). Issues regarding safety and adverse effects of bevacizumab are discussed. To the best of our knowledge, this is the first reported case of hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal CSC.